Laurion Capital Management LP acquired a new position in shares of Clovis Oncology, Inc. (NASDAQ:CLVS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 50,232 shares of the biopharmaceutical company’s stock, valued at approximately $4,703,000. Laurion Capital Management LP owned about 0.11% of Clovis Oncology at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of CLVS. FMR LLC raised its position in shares of Clovis Oncology by 271.4% during the first quarter. FMR LLC now owns 1,816,859 shares of the biopharmaceutical company’s stock worth $115,679,000 after acquiring an additional 1,327,703 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Clovis Oncology by 10,143.6% during the first quarter. Wellington Management Group LLP now owns 1,331,669 shares of the biopharmaceutical company’s stock worth $84,788,000 after acquiring an additional 1,318,669 shares during the last quarter. Jennison Associates LLC raised its position in shares of Clovis Oncology by 222.5% during the second quarter. Jennison Associates LLC now owns 1,185,177 shares of the biopharmaceutical company’s stock worth $110,968,000 after acquiring an additional 817,677 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of Clovis Oncology by 1,538.0% during the first quarter. Alliancebernstein L.P. now owns 754,122 shares of the biopharmaceutical company’s stock worth $48,015,000 after acquiring an additional 708,082 shares during the last quarter. Finally, Franklin Resources Inc. raised its position in shares of Clovis Oncology by 70.3% during the second quarter. Franklin Resources Inc. now owns 1,665,200 shares of the biopharmaceutical company’s stock worth $155,913,000 after acquiring an additional 687,300 shares during the last quarter. Institutional investors own 99.03% of the company’s stock.

CLVS has been the subject of a number of analyst reports. J P Morgan Chase & Co set a $72.00 price objective on Clovis Oncology and gave the stock a “buy” rating in a research report on Thursday, June 1st. ValuEngine upgraded Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Leerink Swann initiated coverage on Clovis Oncology in a research report on Tuesday, June 13th. They set an “outperform” rating and a $85.00 price objective for the company. Credit Suisse Group restated an “outperform” rating and set a $88.00 price objective on shares of Clovis Oncology in a research report on Friday, June 16th. Finally, Chardan Capital upgraded Clovis Oncology from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $36.00 to $50.00 in a report on Monday, June 19th. Nine investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $84.91.

ILLEGAL ACTIVITY WARNING: “Laurion Capital Management LP Acquires Shares of 50,232 Clovis Oncology, Inc. (CLVS)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/18/laurion-capital-management-lp-acquires-shares-of-50232-clovis-oncology-inc-clvs.html.

Shares of Clovis Oncology, Inc. (NASDAQ CLVS) opened at 69.485 on Monday. The stock’s 50 day moving average price is $74.21 and its 200 day moving average price is $68.78. Clovis Oncology, Inc. has a 12-month low of $25.50 and a 12-month high of $99.45. The company’s market cap is $3.40 billion.

Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.02). The firm had revenue of $14.62 million during the quarter, compared to analysts’ expectations of $13.07 million. During the same period in the prior year, the company earned ($2.07) earnings per share. The business’s quarterly revenue was down 32.5% on a year-over-year basis. On average, analysts forecast that Clovis Oncology, Inc. will post ($7.56) EPS for the current year.

In other news, Director James C. Blair sold 18,450 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $78.61, for a total value of $1,450,354.50. Following the completion of the transaction, the director now owns 2,185 shares of the company’s stock, valued at approximately $171,762.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $70.05, for a total value of $210,150.00. Following the completion of the transaction, the insider now directly owns 194,583 shares of the company’s stock, valued at approximately $13,630,539.15. The disclosure for this sale can be found here. Insiders sold a total of 24,450 shares of company stock valued at $1,935,185 in the last three months. Corporate insiders own 17.40% of the company’s stock.

Clovis Oncology Profile

Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Stock Ratings for Clovis Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology Inc. and related stocks with our FREE daily email newsletter.